MedTrace Logo

Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population

NCT05480436 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2022-08-30

No results posted yet for this study

Summary

Evaluation of immunogenicity and safety of inactivated COVID-19 vaccine (BBIBP-Corv) coadministered with PPV23 and IIV4 in hemodialysis population.

Conditions

Interventions

BIOLOGICAL

coadministration

the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and IIV4 on Day 0, and the coadministration of BBIBP-CorV and PPV23 on Day 28

BIOLOGICAL

COVID-19 vaccine

received two doses of inactivated COVID-19 vaccine (BBIBP-CorV)

BIOLOGICAL

IIV4+PPV23

received one dose of IIV4 on Day 0, and one dose of PPV23 on Day 28

Sponsors & Collaborators

  • Hunan Provincial Center for Disease Control and Prevention

    collaborator OTHER

  • Sichuan Center for Disease Control and Prevention

    collaborator OTHER_GOV

  • Guizhou Center for Disease Control and Prevention

    collaborator OTHER

  • Xiangya Hospital of Central South University

    collaborator OTHER

  • Beijing Institute of Biological Products Co Ltd.

    collaborator INDUSTRY

  • Chengdu Institute of Biological Products Co.,Ltd.

    collaborator INDUSTRY

  • Shanghai Institute Of Biological Products

    collaborator INDUSTRY

  • China National Biotec Group Company Limited

    lead INDUSTRY

Principal Investigators

  • Tao Huang · Hunan Provincial Center for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-05
Primary Completion
2023-01-30
Completion
2023-07-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05480436 on ClinicalTrials.gov